24672585|t|Longitudinal PET imaging of muscular inflammation using 18F-DPA-714 and 18F-Alfatide II and differentiation with tumors.
24672585|a|AIM: (18)F-DPA-714 is a PET tracer that recognizes macrophage translocator protein (TSPO), and (18)F-Alfatide II ((18)F-AlF-NOTA-E[PEG4-c(RGDfk)]2) is specific for integrin alphavbeta3. This study aims to apply these two tracers for longitudinal PET imaging of muscular inflammation, and evaluate the value of (18)F-DPA-714 in differentiating inflammation from tumor. METHODS: RAW264.7 mouse macrophage cells were used for cell uptake analysis of (18)F-DPA-714. A mouse hind limb muscular inflammation model was established by intramuscular injection of turpentine oil. For the inflammation model, PET imaging was performed at different days using (18)F-DPA-714 and (18)F-Alfatide II. The specificity of the imaging probes was tested by co- or pre-injection of PK11195 or unlabeled RGD (Arg-Gly-Asp) peptide. PET imaging using (18)F-DPA-714 was performed in A549, HT29, U87MG, INS-1, and 4T1 xenograft models. Immunofluorescence staining was performed to evaluate infiltrated macrophages and angiogenesis in inflammation and/or tumors. RESULTS: Uptake of (18)F-DPA-714 in RAW264.7 cells was 45.5% at 1 h after incubation, and could be blocked by PK11195. PET imaging showed increased (18)F-DPA-714 and (18)F-Alfatide II uptake at inflammatory muscles. Peak uptake of (18)F-DPA-714 was seen on day 6 (4.02 +- 0.64 %ID/g), and peak uptake of (18)F-Alfatide II was shown on day 12 (1.87 +- 0.35 %ID/g) at 1 h p.i.. Tracer uptakes could be inhibited by PK11195 for (18)F-DPA-714 or cold RGD for (18)F-Alfatide II. Moreover, macrophage depletion with liposomal clodronate also reduced the local accumulation of both tracers. A549, HT29, U87MG, INS-1, and 4T1 tumor uptakes of (18)F-DPA-714 (0.46 +- 0.28, 0.91 +- 0.08, 1.69 +- 0.67, 1.13 +- 0.33, 1.22 +- 0.55 %ID/g at 1 h p.i., respectively) were significantly lower than inflammation uptake (All P < 0.05). CONCLUSION: PET imaging using (18)F-DPA-714 as a TSPO targeting tracer could evaluate the dynamics of macrophage activation and infiltration in different stages of inflammatory diseases. The concomitant longitudinal PET imaging with both (18)F-DPA-714 and (18)F-Alfatide II matched the causal relationship between macrophage infiltration and angiogenesis. Moreover, we found (18)F-DPA-714 uptake in several types of tumors is significantly lower than that in inflammatory muscles, suggesting (18)F-DPA-714 PET has the potential for better differentiation of tumor and non-tumor inflammation.
24672585	28	49	muscular inflammation	Disease	MESH:D007249
24672585	56	67	18F-DPA-714	Chemical	-
24672585	72	87	18F-Alfatide II	Chemical	MESH:C586680
24672585	113	119	tumors	Disease	MESH:D009369
24672585	126	139	(18)F-DPA-714	Chemical	-
24672585	205	209	TSPO	Gene	12257
24672585	216	233	(18)F-Alfatide II	Chemical	MESH:C586680
24672585	235	267	(18)F-AlF-NOTA-E[PEG4-c(RGDfk)]2	Chemical	MESH:C586680
24672585	382	403	muscular inflammation	Disease	MESH:D007249
24672585	431	444	(18)F-DPA-714	Chemical	-
24672585	464	476	inflammation	Disease	MESH:D007249
24672585	482	487	tumor	Disease	MESH:D009369
24672585	498	506	RAW264.7	CellLine	CVCL:0493
24672585	507	512	mouse	Species	10090
24672585	568	581	(18)F-DPA-714	Chemical	-
24672585	585	590	mouse	Species	10090
24672585	601	622	muscular inflammation	Disease	MESH:D007249
24672585	675	689	turpentine oil	Chemical	MESH:D014425
24672585	699	711	inflammation	Disease	MESH:D007249
24672585	769	782	(18)F-DPA-714	Chemical	-
24672585	787	804	(18)F-Alfatide II	Chemical	MESH:C586680
24672585	882	889	PK11195	Chemical	MESH:C037850
24672585	903	906	RGD	Chemical	MESH:C047981
24672585	908	919	Arg-Gly-Asp	Chemical	MESH:C047981
24672585	921	928	peptide	Chemical	MESH:D010455
24672585	948	961	(18)F-DPA-714	Chemical	-
24672585	979	983	A549	CellLine	CVCL:0023
24672585	985	989	HT29	CellLine	CVCL:0320
24672585	991	996	U87MG	CellLine	CVCL:0022
24672585	998	1003	INS-1	CellLine	CVCL:0352
24672585	1009	1012	4T1	CellLine	CVCL:0125
24672585	1129	1141	inflammation	Disease	MESH:D007249
24672585	1149	1155	tumors	Disease	MESH:D009369
24672585	1176	1189	(18)F-DPA-714	Chemical	-
24672585	1193	1201	RAW264.7	CellLine	CVCL:0493
24672585	1267	1274	PK11195	Chemical	MESH:C037850
24672585	1305	1318	(18)F-DPA-714	Chemical	-
24672585	1323	1340	(18)F-Alfatide II	Chemical	MESH:C586680
24672585	1351	1363	inflammatory	Disease	MESH:D007249
24672585	1388	1401	(18)F-DPA-714	Chemical	-
24672585	1461	1478	(18)F-Alfatide II	Chemical	MESH:C586680
24672585	1570	1577	PK11195	Chemical	MESH:C037850
24672585	1582	1595	(18)F-DPA-714	Chemical	-
24672585	1604	1607	RGD	Chemical	MESH:C047981
24672585	1612	1629	(18)F-Alfatide II	Chemical	MESH:C586680
24672585	1677	1687	clodronate	Chemical	MESH:D004002
24672585	1741	1745	A549	CellLine	CVCL:0023
24672585	1747	1751	HT29	CellLine	CVCL:0320
24672585	1753	1758	U87MG	CellLine	CVCL:0022
24672585	1760	1765	INS-1	CellLine	CVCL:0352
24672585	1771	1774	4T1	CellLine	CVCL:0125
24672585	1775	1780	tumor	Disease	MESH:D009369
24672585	1792	1805	(18)F-DPA-714	Chemical	-
24672585	1939	1951	inflammation	Disease	MESH:D007249
24672585	2005	2018	(18)F-DPA-714	Chemical	-
24672585	2024	2028	TSPO	Gene	12257
24672585	2139	2160	inflammatory diseases	Disease	MESH:D007249
24672585	2213	2226	(18)F-DPA-714	Chemical	-
24672585	2231	2248	(18)F-Alfatide II	Chemical	MESH:C586680
24672585	2350	2363	(18)F-DPA-714	Chemical	-
24672585	2391	2397	tumors	Disease	MESH:D009369
24672585	2434	2446	inflammatory	Disease	MESH:D007249
24672585	2467	2480	(18)F-DPA-714	Chemical	-
24672585	2533	2538	tumor	Disease	MESH:D009369
24672585	2547	2552	tumor	Disease	MESH:D009369
24672585	2553	2565	inflammation	Disease	MESH:D007249
24672585	Association	MESH:C586680	MESH:D007249
24672585	Positive_Correlation	MESH:D014425	MESH:D007249

